Hendrik Schulze‐koops

Hendrik Schulze‐koops's AcademicInfluence.com Rankings

Philosophy

#9087

World Rank

#12592

Historical Rank

Logic

#6081

World Rank

#7563

Historical Rank

philosophy Degrees

Hendrik Schulze‐koops

Biology

#12428

World Rank

#15903

Historical Rank

Immunology

#831

World Rank

#854

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Hendrik Schulze‐koops's Degrees

Doctorate Medicine Stanford University

Why Is Hendrik Schulze‐koops Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hendrik Schulze‐koops's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. (2012) (802)
Trial of Tocilizumab in Giant‐Cell Arteritis (2017) (798)
Role of Th17 cells in human autoimmune arthritis. (2010) (416)
Treg cells suppress osteoclast formation: a new link between the immune system and bone. (2007) (316)
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial (2013) (310)
Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose (1999) (308)
The role of the T cell in autoimmune inflammation (2005) (279)
The balance of Th1/Th2 cytokines in rheumatoid arthritis. (2001) (260)
The central role of T cells in rheumatoid arthritis. (2007) (248)
Elevated interleukin-10 levels in patients with rheumatoid arthritis. (1995) (248)
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 (2020) (208)
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease (2017) (192)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) (2011) (189)
The IL-4 Receptor α-Chain-Binding Cytokines, IL-4 and IL-13, Induce Forkhead Box P3-Expressing CD25+CD4+ Regulatory T Cells from CD25−CD4+ Precursors1 (2005) (180)
Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis (2014) (162)
Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. (1995) (147)
European consensus statement on the terminology used in the management of lupus glomerulonephritis (2009) (137)
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry (2021) (131)
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment (2017) (123)
Plasmid-encoded outer membrane protein YadA mediates specific binding of enteropathogenic yersiniae to various types of collagen (1992) (115)
Outer membrane protein YadA of enteropathogenic yersiniae mediates specific binding to cellular but not plasma fibronectin (1993) (114)
Regulatory T cells in rheumatoid arthritis (2005) (113)
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab (2020) (112)
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors (2020) (112)
Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. (1998) (109)
GATA-3 in Human T Cell Helper Type 2 Development (2004) (108)
Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis (2011) (107)
Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade (2006) (105)
Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. (1997) (103)
The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells (2006) (90)
Altered memory T cell differentiation in patients with early rheumatoid arthritis. (1999) (86)
Relevance of grade 1 gray-scale ultrasound findings in wrists and small joints to the assessment of subclinical synovitis in rheumatoid arthritis. (2013) (85)
Restriction of De Novo Pyrimidine Biosynthesis Inhibits Th1 Cell Activation and Promotes Th2 Cell Differentiation1 (2002) (84)
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway: Commentary (2011) (83)
Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report (2012) (81)
Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. (2006) (80)
Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis (2014) (77)
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID) (2013) (72)
Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. (2012) (71)
Sonographic and clinical pattern of extracranial and cranial giant cell arteritis (2012) (68)
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases (2021) (67)
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein (2008) (66)
Cytokine mRNA and protein expression in primary-culture and repeated-passage synovial fibroblasts from patients with rheumatoid arthritis (2001) (65)
Expression of CD45RB and CD27 identifies subsets of CD4+ memory T cells with different capacities to induce B cell differentiation. (1995) (65)
Lymphopenia and autoimmune diseases (2004) (64)
Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab (2019) (64)
Severe septicaemia in a patient with polychondritis and Sweet’s syndrome after initiation of treatment with infliximab (2003) (63)
Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy (2018) (63)
[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]. (2018) (59)
Interaction of enteropathogenic Yersinia enterocolitica with complex basement membranes and the extracellular matrix proteins collagen type IV, laminin-1 and -2, and nidogen/entactin. (1994) (59)
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies (2017) (57)
Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis (2007) (56)
Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure (2012) (55)
Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. (1998) (54)
Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial (2020) (52)
Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). (2019) (52)
Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. (2014) (52)
miR-142-3p Is Involved in CD25+ CD4 T Cell Proliferation by Targeting the Expression of Glycoprotein A Repetitions Predominant (2013) (51)
Generation and Regulation of Human Th1-Biased Immune Responses In Vivo: A Critical Role for IL-4 and IL-10 1 (2004) (51)
Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases (2012) (50)
The role of the immune response against tissue transglutaminase in the pathogenesis of coeliac disease. (2004) (50)
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update (2022) (50)
Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. (1997) (48)
Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. (2019) (47)
Disease burden, disease manifestations and current treatment regimen of the SAPHO syndrome in Germany: results from a nationwide patient survey. (2014) (46)
Antigen-Independent Th2 Cell Differentiation by Stimulation of CD28: Regulation Via IL-4 Gene Expression and Mitogen-Activated Protein Kinase Activation1 (2001) (46)
Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. (2015) (45)
Rheumatoid synovial CD4+ T cells exhibit a reduced capacity to differentiate into IL-4-producing T-helper-2 effector cells (2000) (44)
Anti-CD4 monoclonal antibody therapy in human autoimmune diseases. (2000) (44)
Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. (2016) (43)
Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic (2020) (43)
The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. (2019) (43)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update (2022) (42)
Involvement of the Femoropopliteal Arteries in Giant Cell Arteritis: Clinical and Color Duplex Sonography (2012) (42)
B-mode sonography wall thickness assessment of the temporal and axillary arteries for the diagnosis of giant cell arteritis: a cohort study. (2017) (42)
Dosing down with biologic therapies: a systematic review and clinicians’ perspective (2017) (42)
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52 (2020) (41)
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD (2020) (41)
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial (2020) (40)
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. (2017) (40)
The p38 mitogen‐activated protein kinase regulates effector functions of primary human CD4 T cells (2005) (40)
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. (2012) (40)
Fever of unknown origin as initial manifestation of large vessel giant cell arteritis: diagnosis by colour-coded sonography and 18-FDG-PET. (2010) (39)
Dosing down with biologic therapies: a systematic review and clinicians’ perspective (2017) (39)
3D-black-blood 3T-MRI for the diagnosis of thoracic large vessel vasculitis: A feasibility study (2016) (38)
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID) (2015) (37)
The effect of the pro-inflammatory cytokine tumor necrosis factor-alpha on human joint capsule myofibroblasts (2010) (37)
Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID) (2012) (37)
Cardiomyopathy in Murine Models of Systemic Sclerosis (2015) (36)
Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm (2017) (36)
Human memory T cell differentiation into Th2‐like effector cells is dependent on IL‐4 and CD28 stimulation and inhibited by TCR ligation (1998) (35)
Initial presenting manifestations in 16,486 patients with Inborn Errors of Immunity include infections and non-infectious manifestations. (2021) (35)
Gustatory and olfactory function in rheumatoid arthritis (2011) (35)
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts (2019) (33)
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial (2021) (33)
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19 (2021) (32)
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs (2013) (31)
Purification and analytical characterization of an anti-CD4 monoclonal antibody for human therapy. (1994) (30)
Th17 cells in autoimmune arthritis (2010) (30)
Immature and Maturation-Resistant Human Dendritic Cells Generated from Bone Marrow Require Two Stimulations to Induce T Cell Anergy In Vitro (2009) (29)
Ultrasound of Synovitis in Rheumatoid Arthritis: Advantages of the Dorsal over the Palmar Approach to Finger Joints (2014) (27)
Prognostic factors in rheumatoid arthritis in the era of biologic agents (2009) (27)
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study (2013) (27)
Plasmapheresis therapy in an elderly patient with rapidly progressive Henoch-Schönlein purpura with disseminated organ involvement (2005) (26)
Increased Th17 Cell Frequency and Poor Clinical Outcome in Rheumatoid Arthritis Are Associated With a Genetic Variant in the IL4R Gene, rs1805010 (2014) (26)
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab (2016) (26)
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines (2021) (25)
Activation of pregnane X receptor inhibits experimental dermal fibrosis (2013) (24)
Characterization of the binding region for the Yersinia enterocolitica adhesin YadA on types I and II collagen. (1995) (24)
Outcome of giant cell arteritis of the arm arteries managed with medical treatment alone: cross-sectional follow-up study. (2013) (24)
T cell activation as starter and motor of rheumatic inflammation. (2006) (23)
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study (2018) (23)
Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. (2005) (23)
Digital Health Transition in Rheumatology: A Qualitative Study (2021) (23)
Human CD4 modulation in vivo induced by antibody treatment. (1993) (23)
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial): Commentary (2011) (21)
Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. (2015) (21)
Age-related impairment of T cell proliferative responses related to the decline of CD28+ T cell subsets. (1997) (20)
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial (2018) (20)
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 (2021) (20)
Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey (2017) (19)
Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis (2019) (19)
Induction of cyclooxygenase-2 and enhanced release of prostaglandin E(2) and I(2) in human endothelial cells by engagement of CD40. (2002) (18)
Fibrinogen and factor XIII A-subunit genotypes interactively influence C-reactive protein levels during inflammation (2012) (18)
The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis (2014) (18)
Assessment of Disease Activity in Takayasu Arteritis: Potential Role of Contrast-Enhanced Ultrasound (2019) (17)
Gustatory and olfactory function in patients with granulomatosis with polyangiitis (Wegener’s) (2014) (17)
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. (2021) (16)
Methylation of an intragenic alternative promoter regulates transcription of GARP. (2016) (16)
Analysis of the Transcriptional Program of Developing Induced Regulatory T Cells (2011) (16)
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study (2019) (16)
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry (2020) (16)
Mast cells express IL-17A in rheumatoid arthritis synovium: Commentary (2010) (16)
Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. (2021) (16)
Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. (2013) (16)
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD (2021) (15)
The p 38 mitogen-activated protein kinase signaling cascade in CD 4 T cells (14)
Persistent reduction in IL‐6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM‐1) (1996) (14)
THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY) (2019) (14)
The influence of long distance running on sonographic joint and tendon pathology: results from a prospective study with marathon runners (2016) (14)
Analysis of Th1/Th2 T-cell subsets. (2007) (14)
[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. (2016) (14)
The immune reconstitution inflammatory syndrome in whipple disease: A cohort study. Commentary (2011) (13)
Diagnostic accuracy of positron emission tomography for assessment of disease activity in large vessel vasculitis (2018) (13)
[Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic]. (2020) (13)
Regulatory T cells suppress osteoclast formation: A new link between the immune system and bone (2008) (13)
Cytotoxic T cells go awry in inclusion body myositis. (2016) (13)
Ocular ischaemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment. (2019) (13)
Human CD4+ T cell differentiation and effector function (1999) (13)
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort (2018) (12)
A Rare Side Effect of Checkpoint Inhibitor Therapy—Nivolumab‐Induced Axial Polyarthritis of the Facet and Costovertebral Joints (2019) (12)
Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register - Commentary (2011) (12)
Patient and Physician Expectations of Add‐On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes (2014) (12)
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM) (2016) (12)
Homotypic T-cell/T-cell interaction induces T-cell activation, proliferation, and differentiation. (2009) (12)
What we have learned from trials of immunomodulatory agents in rheumatoid arthritis: Future directions. (1999) (12)
Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer- binding protein alpha: Commentary (2010) (12)
[Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF]. (2017) (12)
Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency (2006) (11)
Increased plasticity of non-classic Th1 cells toward the Th17 phenotype (2020) (11)
Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor a therapy: Results from the nationwide Danish DANBIO registry - Commentary (2011) (11)
Tuberculous Spondylitis (Pott’s Disease) (2008) (11)
[Rheumatology - Integration into student training (RISA) : Current structure of clinical rheumatology in German universities (RISA III)]. (2016) (11)
Feasibility and reproducibility of the PsAMRIS-H score for psoriatic arthritis in low-field-strength dedicated extremity magnetic resonance imaging (2013) (11)
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year - Commentary (2011) (11)
Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children. (1995) (10)
Surfactant-free poly(styrene-co-glycidyl methacrylate) particles with surface-bound antibodies for activation and proliferation of human T cells. (2010) (10)
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2 - methodology, key messages and justifying information. (2021) (10)
[S2k guidelines: management of large-vessel vasculitis]. (2020) (10)
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study (2020) (10)
Assessment of autonomic function in a cohort of patients with ANCA-associated vasculitis (2016) (9)
Dysregulated immunity in PID patients with low GARP expression on Tregs due to mutations in LRRC32 (2021) (9)
[Revised version of the statement by the DGRh on biosimilars-update 2017]. (2018) (9)
Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard: Commentary (2010) (9)
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol (2019) (9)
Use of the 28-Joint Count Yields Significantly Higher Concordance Between Different Examiners Than the 66/68-Joint Count (2012) (9)
[Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga"]. (2016) (9)
Relapses in three patients with Takayasu arteritis under tocilizumab treatment detected by contrast enhanced ultrasound. (2018) (9)
Schnitzler's Disease as an Important Differential Diagnosis of Chronic Recurrent Multifocal Osteomyelitis: A Case Report (2012) (8)
TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases (2021) (8)
Adulter Morbus Still (2008) (8)
IgG4-related sialadenitis: IgG4 is helpful, but biopsies are still crucial (2015) (7)
Altered T cell plasticity favours Th17 cells in early arthritis. (2020) (7)
Combination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue disease. (2006) (7)
Treatment of rheumatoid arthritis in the third millennium. (2001) (7)
[Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020]. (2020) (7)
An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritis: Commentary (2010) (7)
Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis? (2021) (7)
MHC class II expression on myeloid cells inversely correlates with disease progression in early rheumatoid arthritis. (2007) (7)
Immune regulation by peripheral suppressor T cells induced upon homotypic T cell/T cell interactions (2010) (7)
Temporal artery compression sonography for the diagnosis of giant cell arteritis in elderly patients with acute ocular arterial occlusions. (2020) (6)
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. (2021) (6)
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial (2022) (6)
FRI0129 Switch between reference etanercept (ETN) and gp2015, an etanercept biosimilar, did not impact efficacy and safety in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase 3 equira study (2018) (6)
Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al (2020) (6)
Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation: Commentary (2011) (6)
Response to: ‘Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak’ by So et al (2020) (6)
Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re-Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study (2017) (5)
Lack of genetic association of the interleukin-4 receptor single-nucleotide polymorphisms I50V and Q551R with erosive disease in psoriatic arthritis. (2006) (5)
The Th2 cytokines IL-4 and IL-10 are internal controllers of human Th1-biased immunity in vivo (2003) (5)
Leflunomide: an immunosuppressive drug with multiple effects on T cell function (2002) (5)
THU0198 Patient Evaluations of Autoinjectors for Delivery of Subcutaneous Golimumab for Treatment of Rheumatoid Arthritis (2013) (5)
[Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases : Experiences from a German registry (GRAID2)]. (2018) (5)
Adult-onset Still's disease in a patient with cystic fibrosis and its successful treatment with anakinra. (2012) (5)
Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA. (2019) (5)
[Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination]. (2021) (5)
THU0649 PHENOTYPIC CLUSTERS OF RHEUMATIC/SYSTEMIC IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES (IMMUNOCANCER INTERNATIONAL REGISTRY) (2019) (4)
Methotrexate does not increase the risk of liver fibrosis in patients with rheumatoid arthritis: assessment by ultrasound elastography (ARFI-MetRA study) (2021) (4)
Autosplenectomy: rare syndrome in autoimmunopathy (2006) (4)
Pupillary autonomic dysfunction in patients with ANCA-associated vasculitis (2017) (4)
Th17 cells expressing KIR3DL2 + and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis: Commentary (2011) (4)
[T-lymphocytes--do they control rheumatic immune responses?]. (2005) (4)
THU0155 Predictors of Low Disease Activity and Remission after One Dose of Golimumab in Patients with Rheumatoid Arthritis (2014) (4)
Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS): Commentary (2011) (4)
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study (2022) (4)
Where is biological therapy going? (2000) (4)
[Vaccination against SARS-CoV-2 in inflammatory rheumatic diseases : Recommendations of the German Society for Rheumatology for physicians and patients]. (2021) (4)
Chicken and egg in autoimmunity and joint inflammation. (2001) (4)
Anti-CD4 monoclonal antibody immune intervention in patients with newly diagnosed Type I (insulin-dependent) diabetes mellitus (1994) (4)
Diagnostic yield of axillary artery ultrasound in addition to temporal artery ultrasound for the diagnosis of giant cell arteritis. (2022) (4)
Fatal Spontaneous Bilateral Vertebral Artery Dissection in Giant Cell Arteritis (GCA) (2017) (4)
A Diagnostic Algorithm Based on a Simple Clinical Prediction Rule for the Diagnosis of Cranial Giant Cell Arteritis (2021) (4)
OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN’S SYNDROME (2020) (4)
Inflammation: TREG cell control of autoimmune inflammation: a matter of timing? (2010) (4)
Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des Polyarthrites Indifférenciées Récentes (Study and Followup of Early Undifferentiated Polyarthritis) - Commentary (2011) (4)
CO0004 OLDER AGE, CARDIOVASCULAR COMORBIDITY AND GLUCOCORTICOSTEROIDS ARE RISK FACTORS FOR COVID-19 HOSPITALISATION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: FIRST RESULTS OF THE GERMAN COVID-19-IRD REGISTRY (2020) (3)
Erratum to: The influence of long distance running on sonographic joint and tendon pathology: results from a prospective study with marathon runners (2016) (3)
Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate-treated rheumatoid arthritis patients in OPTIMA. (2019) (3)
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Commentary (2011) (3)
3D black-blood 3T-MRI for the diagnosis of abdominal large vessel vasculitis (2019) (3)
Remission of Demyelinating Polyneuropathy With Immunoadsorption, Low Dose Corticosteroids and Anti‐CD20 Monoclonal Antibody (2008) (3)
Comment on: induction treatment of ANCA-associated vasculitis with a single dose of rituximab. (2015) (3)
Th1/Th2 cytokine balance in arthritis: comment on the article by Miossec and van den Berg. (1998) (3)
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: Commentary (2010) (3)
[Rituximab for the treatment of poly- and dermatomyositis : Results from the GRAID-2 registry]. (2018) (3)
A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany (2021) (3)
[Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)]. (2018) (3)
The virtual fishbowl: bringing back dynamic debates to medical conferences (2020) (3)
[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis]. (2005) (3)
OP0165 EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY (2019) (3)
Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort (2018) (3)
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination (2021) (3)
[Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study]. (2009) (3)
AB0497 Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the st. gallen and aarau cohort (2018) (3)
[Current state of vaccination against SARS-CoV-2]. (2021) (3)
Treatment of rheumatic diseases: a companion to Kelley's textbook of rheumatology (2002) (2)
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). (2019) (2)
Very early rheumatoid arthritis is the major predictor of major outcomes: Clinical ACR remission and radiographic non-progression - Commentary (2011) (2)
[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)]. (2018) (2)
THU0515 Hypogammaglobulinemia is a Frequent Finding in Patients Under Immunosuppressive Therapy but Does not Correlate with Susceptibility to Infections (2013) (2)
Gender differences in giant cell arteritis: a case-control study. (2016) (2)
FRI0606 Characteristics and treatment of new onset arthritis after checkpoint inhibitor therapy (2017) (2)
SAT0531 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the giacta trial (2018) (2)
Hyperechogenic intimal lesions and wall thickness of the temporal and facial arteries in elderly patients with arterial occlusions of the eye (2021) (2)
272 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial (2019) (2)
Induction of Th2 cell differentiation by cognate interaction of CD4 memory T cells (2002) (2)
EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy (2019) (2)
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis: Commentary (2011) (2)
[Th9 cells. Functionally important or just an epiphenomenon?]. (2012) (2)
[Biomarkers in rheumatology. Biomarkers and imaging for the diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the ArthroMark network funded by the Federal Ministry of Education and Research]. (2012) (2)
Evaluation of a Novel Semi-Automated Ultrasound System for the Detection of Synovitis: A Prospective Study involving 45 Patients with Rheumatoid Arthritis (2016) (2)
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: Analysis of the PRINTO methotrexate trial - Commentary (2010) (2)
Immunosuppression with biologicals: prospects for the treatment of autoimmune diseases (2002) (2)
Synovial inflammation in patients undergoing arthroscopic meniscectomy: Molecular characterization and relationship to symptoms. Commentary (2011) (2)
[Inflammatory aortic diseases]. (2013) (2)
Expression and regulation of CCL 18 in synovial fluid neutrophils of patients with rheumatoid arthritis (2015) (2)
FRI0697 Expectations, motivating factors and barriers to basic research among young rheumatologists in germany– results of a national online survey (2018) (2)
After 25 years of drug development, do we know JAK? (2022) (2)
The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis (2021) (2)
Obstacles to Anti-CD4 Therapy in Rheumatoid Arthritis (1999) (2)
AB1033 Evidence for Autonomic Dysfunction in Familial Mediterranean Fever (FMF): Results from a Prospective Controlled Study Including the Compass-31 Questionnaire (2015) (2)
Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients: Commentary (2011) (2)
Treatment strategies aiming at remission in early rheumatoid arthritis patients: Starting with methotrexate monotherapy is cost-effective - Commentary (2011) (2)
The Value of an Automated Ultrasound System in the Detection of Synovitis (2014) (2)
Altered T Cell Differentiation in Patients with Early Rheumatoid Arthritis (1999) (2)
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel) (2022) (2)
Reactive arthritis after SARS-CoV-2 infection (2022) (2)
THU0561 CANAKINUMAB FOR THE TREATMENT OF ADULT ONSET STILL‘S DISEASE TO ACHIEVE REDUCTION OF ARTHRITIC MANIFESTATION AT WEEK 12: AN INVESTIGATOR-INITIATED MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER) (2019) (2)
[Annual meeting of the German Society for Rheumatology going virtual-successfully defying the pandemic]. (2021) (2)
Rheumatology, third edition (2004) (2)
Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a Phase II, randomized, placebo-controlled, dose-finding trial - Commentary (2011) (1)
IFNGR1 single nucleotide polymorphisms in rheumatoid arthritis (2006) (1)
POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS (2021) (1)
Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e. V.) (2020) (1)
[Morbus Bechterew - diagnosis and therapy]. (2019) (1)
BHPR research: qualitative1. Complex reasoning determines patients’ perception of outcome following foot surgery in rheumatoid arhtritis (2012) (1)
Rheumatoid arthritis-interstitial lung disease-associated mortality: Commentary (2011) (1)
Induction of peripheral Tregs by homotypic T cell interaction (89.3) (2009) (1)
[Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e. V.) : We live rheumatology. German version]. (2020) (1)
T cells – overview – update (2007) (1)
MRI in early rheumatoid arthritis: Synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression: Commentary (2011) (1)
Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-associated cardiovascular risk? Commentary (2010) (1)
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Commentary (2011) (1)
A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: The HEEL trial - Commentary (2010) (1)
The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease. (2022) (1)
[Future of acute inpatient rheumatology in Germany : Statement of the Boards of the German Society for Rheumatology and the Association of Rheumatological Acute Clinics on hospital planning North-Rhine/Westphalia 2019 for the discipline rheumatology]. (2020) (1)
Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis: Commentary (2011) (1)
[Immunology of systemic inflammatory diseases]. (2018) (1)
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents: Commentary (2011) (1)
Joachim Robert Kalden: one of the founders of autoimmunity research and immunotherapy (2021) (1)
A complex pattern of autonomic dysfunction in familial Mediterranean fever. Results from a controlled cross-sectional study. (2019) (1)
The comparative safety of analgesics in older adults with arthritis: Commentary (2011) (1)
Response to: ‘Should patients starting biologics be screened for COVID-19?’ by Cardenas-de la Garza et al (2020) (1)
[Th17 cells - a new proinflammatory T cell population and its role in rheumatologic autoimmune diseases]. (2009) (1)
No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: Results from a longitudinal comparative MRI, ultrasonography, CT and radiography study - Commentary (2011) (1)
[Development of quality standards for patients with axial spondyloarthritis for use in Germany]. (2021) (1)
[New biologics and orally available compounds. What is still in the pipeline?]. (2010) (1)
OP0131 Optimal dose of tocilizumab for the treatment of giant cell arteritis: efficacy, safety, and exposure-efficacy analysis from giacta (2017) (1)
Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome: Commentary (2011) (1)
[Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)]. (2018) (1)
Diffuse large B‐cell lymphoma on the back of a patient with AIDS: Successful treatment by the CD20 monoclonal antibody rituximab (2005) (1)
Musculoskeletal pain is associated with very low levels of vitamin D in men: Results from the European Male Ageing Study - Commentary (2010) (1)
DEK in the synovium of JIA patients: Characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Commentary (2011) (1)
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system: Commentary (2011) (1)
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): A 48- week randomised controlled trial - Commentary (2011) (1)
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial: Commentary (2010) (1)
[S2k guidelines (executive summary): management of large-vessel vasculitis]. (2020) (1)
Prevention of flare recurrences in childhood-refractory chronic uveitis: An open-label comparative study of adalimumab versus infliximab - Commentary (2011) (1)
Correspondence to ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’ (2020) (1)
Response to: ‘Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience’ by Pineda-Sic et al (2020) (1)
POS1261 DISEASE ACTIVITY AND PAIN LEVELS ARE NOT INFLUENCED BY THE CURRENT COVID19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES IN GERMANY – DATA FROM THE GERMAN COVID-19 PATIENT SURVEY (2021) (1)
Paraneoplastic syndrome, infection or arthritis: difficulties in diagnosis * (2006) (1)
THU0400 Inhibition of IL-6 signalling: A novel therapeutic approach for familial mediterranean fever (2013) (1)
Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies (2017) (1)
A rare side effect of methotrexate therapy: drug-induced osteopathy with multiple fractures of the lower limb (2023) (1)
OP0283 DOES TNF-INHIBITION DECREASE THE RISK OF SEVERE COVID-19 IN RMD-PATIENTS? (2021) (1)
SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES (2020) (1)
SAT0517 Automated Ultrasound for the Detection of Joint Swelling in Arthritic Diseases (2013) (1)
Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis: Commentary (2011) (1)
[Cellular therapy in autoimmune disease]. (2009) (1)
Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): A Phase 2, Multi-Centre, Placebo-Controlled Study (2019) (1)
[Do we still need clinical studies in rheumatology?]. (2016) (1)
[Development of quality standards for patients with rheumatoid arthritis for use in Germany]. (2021) (1)
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary (2011) (1)
T Cell-Targeted Therapy for Rheumatoid Arthritis (2007) (1)
Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: Results of the ESTHER trial at week 48 - Commentary (2011) (1)
Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases (2017) (1)
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update (2022) (1)
Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: The ETRA study. Commentary (2011) (0)
Comment on: Temporal artery compression sonography for the diagnosis of giant cell arteritis in elderly patients with acute ocular arterial occlusions. Reply. (2021) (0)
[Superior vena cava syndrome: Catheter association as a rare cause]. (2006) (0)
P022 Checkpoint inhibitors activate store-operated CA2+ entry and ERK1/2 signalling and promote TH17 differentiation (2018) (0)
Prevalence of contraindications and prescription of pharmacologic therapies for gout: Commentary (2011) (0)
Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients: Commentary (2011) (0)
Effects of Concomitant Conventional and Previous Biological Disease Modifying Anti-Rheumatic Drugs Treatment on the Efficacy of Tocilizumab to Induce Remission in Patients with Rheumatoid Arthritis An Observational Real-Life Study (2015) (0)
Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: Commentary (2011) (0)
miRNA regulates the Glycoprotein A repetitions predominant expression in Tregs (113.23) (2011) (0)
T-cell regulation in the pathogenesis of autoimmune diseases (2003) (0)
Ankylosing spondylitis: Patterns of radiographic involvement - A re-examination of accepted principles in a cohort of 769 patients: Commentary (2011) (0)
Adhesion molecules as targets for therapy in rheumatoid arthritis (1996) (0)
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006: Commentary (2011) (0)
AB0273 Very high, but not lower, radiographic progression leads to an increase in haq-di. results from the swiss scqm ra cohort (2017) (0)
The incidence of gastrointestinal perforations among rheumatoid arthritis patients: Commentary (2011) (0)
THU0241 Haemoglobin Changes and Relationship between Anaemia and Fatigue or Vitality in Rheumatoid Arthritis Patients Treated with Tofacitinib (2013) (0)
Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation: Commentary (2011) (0)
[Quality of a multidisciplinary orthopaedic-rheumatological consultation]. (2010) (0)
A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis: Commentary (2011) (0)
CCR5 blockade in rheumatoid arthritis: A randomised, double-blind, placebo-controlled clinical trial. Commentary (2011) (0)
[From cellular pathology to cell therapy]. (2015) (0)
Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study (2022) (0)
SAT0209 Early Response to Tocilizumab (TCZ) and Benefit of Continued TCZ Treatment in Partial TCZ Responders: Results of the Mirai-Study (2015) (0)
Molecular mechanisms of peripheral CD25 regulatory T cell (Treg) development (2010) (0)
22nd European Workshop for Rheumatology Research, Leiden, The Netherlands, 28 February–3 March 2002 (2002) (0)
Musculoskeletal disease burden of hereditary hemochromatosis: Commentary (2011) (0)
Only Very High Radiographic Progression Affects HAQ-DI, Results from the Swiss Scqm Cohort (2017) (0)
SAT0277 Clinical Response in Early Psoriatic Arthritis may be Predicted by Rapid Reduction of a Semiquantitative Ultrasound Synovitis Score (2013) (0)
The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response: Commentary (2011) (0)
Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis: Commentary (2011) (0)
Protein Kinase Activation Gene Expression and Mitogen-Activated by Stimulation of CD28: Regulation Via IL-4 Antigen-Independent Th2 Cell Differentiation (2001) (0)
SAT0201 The Relevance of Flexor Tendon Tenosynovitis to Small Joint Tenderness and Swelling: Data from A Prospective Early RA Cohort (2014) (0)
SAT0535 Diagnosis, Disease Burden and Disease Manifestations of the Sapho Syndrome in Germany: Results from a Nationwide Patient Survey (2013) (0)
Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy: Commentary (2010) (0)
Deutsches Register www.Covid19-Rheuma.de (2021) (0)
[German registry www.Covid19-Rheuma.de : Status report after 1 year of the pandemic]. (2021) (0)
Pathogenetic Concepts of Joint Diseases (2017) (0)
AB1285 Ultrasound of MCP- and PIP-joints in rheumatoid arthritis: Increased value of the dorsal approach compared to the volar approach (2013) (0)
Psoriatic arthritis. (2021) (0)
Pneumococcal antibody levels after Pneumovax in patients with rheumatoid arthritis on methotrexate: Commentary (2011) (0)
Infections in polymyositis and dermatomyositis: Analysis of 192 cases. Commentary (2011) (0)
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples: Commentary (2011) (0)
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials: Commentary (2011) (0)
Recurrent lupus nephritis after kidney transplantation: A surveillance biopsy study. Commentary (2010) (0)
Promotes Th2 Cell Differentiation Biosynthesis Inhibits Th1 Cell Activation and Restriction of De Novo Pyrimidine (2002) (0)
Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia: Commentary (2011) (0)
Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial. Commentary (2011) (0)
The bias for Th1 cell differentiation of rheumatoid arthritis T cells is characteristic of memory but not of naive T cells (2002) (0)
AB0344 EFFICACY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) COMPARED WITH INTRAVENOUS INFLIXIMAB IN RHEUMATOID ARTHRITIS: A POST-HOC ANALYSIS OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2022) (0)
Expert commentary and analysis on recent key papers (2009) (0)
[Hyperuricemia and gout : New aspects of an old disease]. (2016) (0)
Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes. (2021) (0)
AB0270 EFFECTIVENESS OF A SWITCH FROM TOFACITINIB TO BARICITINIB IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA IN SWITZERLAND (2021) (0)
[A Blocked Frontal Sinus with Orbital Swelling]. (2017) (0)
A randomized, double-blind, controlled study of ultrasound-guided corticosteroid injection into the joint of patients with inflammatory arthritis: Commentary (2010) (0)
Antioxidant intake and risks of rheumatoid arthritis and systemic lupus erythematosus in women: Commentary (2010) (0)
Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: Does variable inhibition of interleukin-6 production limit effectiveness in vivo? Commentary (2011) (0)
Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis: Commentary (2011) (0)
Impaired suppression of synovial fluid CD4 +CD25 - T cells from patients with juvenile idiopathic arthritis by CD4 +CD25 + T reg cells: Commentary (2011) (0)
sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study (2022) (0)
Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials - Commentary (2011) (0)
The diagnostic utility of magnetic resonance imaging in spondylarthritis: An international multicenter evaluation of one hundred eighty-seven subjects. Commentary (2011) (0)
Glycoprotein A Repetitions Predominant Proliferation by Targeting the Expression of CD 4 T Cell + miR-1423 p Is Involved in CD 25 (2013) (0)
FRI0274 Assessment of Autonomic Dysfunction in Anca-Associated Vasculitis: A Prospective Study of 24 Patients (2015) (0)
Erosive hand osteoarthritis: Its prevalence and clinical impact in the general population and symptomatic hand osteoarthritis - Commentary (2011) (0)
Long-term impact of delay in assessment of patients with early arthritis: Commentary (2011) (0)
Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells: Commentary (2010) (0)
OP0034 Identification of Genetic Variants Associated with Response to Methotrexate in Patients with Early Rheumatoid Arthritis: Results from the Optima Study (2014) (0)
351. EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2018) (0)
A real-life study of patients with severe asthma and EGPA treated with anti-IL5R (2023) (0)
Means and method for predicting joint destruction (2006) (0)
Early Detection of Richter’s Transformation: Stable Disease with Dose-Reduced Gemcitabine and Local Radiation (2006) (0)
High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Commentary (2010) (0)
Country-Level Factors Associated With COVID-19-Related Death in People With Rheumatic Disease: Results From the COVID-19 Global Rheumatology Alliance Registry (2022) (0)
Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis: Commentary (2011) (0)
1.5 Decades Later: Bearing fruits from the ACR/EULAR exchange Program (2011) (0)
Regulation of T-cell differentiation by IL-4Rα-chain single nucleotide polymorphisms (2004) (0)
COVID-19 vaccination in individuals with inflammatory rheumatic diseases (2022) (0)
SAT0294 Monitoring disease activity in early psoriatic arthritis with ultrasound - comparison of clinical responders and nonresponders (2013) (0)
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomised phase III trial. (2022) (0)
Back pain and total hip arthroplasty: A prospective natural history study - Commentary (2010) (0)
Surgical synovectomy decreases density of sensory nerve fibers in synovial tissue of non-inflamed controls and rheumatoid arthritis patients: Commentary (2011) (0)
THU0275 Interim Analysis of the Retrospective German Registry (GRAID2) (2013) (0)
THU0177 The Influence of Initial Glucocorticoid Therapy on the Progression of Early RA. Results from the Swiss Prospective Observational Registry (2015) (0)
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis: Commentary (2010) (0)
Localized scleroderma: MR findings and clinical features - Commentary (2011) (0)
Immune regulation by peripheral Tregs induced upon homotypic T cell/T cell interactions (2010) (0)
OP0179 CHARACTERISTICS AND OUTCOMES OF SARS-CoV-2 BREAKTHROUGH INFECTIONS AMONG DOUBLE AND TRIPLE VACCINATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES (2022) (0)
OP0185 RADIOGRAPHIC PROGRESSION DESPITE PERSISTENT LDA OR REMISSION IS INFLUENCED BY CURRENT SMOKING RATHER THAN THE RESPECTIVE DAS 28 LEVEL, RESULTS OF THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM) (2021) (0)
SIGIRR/TI R-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflflammation in models of rheumatoid arthritis: Commentary (2010) (0)
AB0045 The orally available immunomodulator rhudex inhibits naÏve and memory T cell activation and proliferation and the release of pro-inflammatory TH1 and TH17 cytokines in vitro (2013) (0)
Review Regulatory T cells in rheumatoid arthritis (2005) (0)
Synovial membrane immunohistology in early untreated juvenile idiopathic arthritis: Differences between clinical subgroups - Commentary (2011) (0)
FRI0066 Leflunomide inhibits proliferation and differentiation of pro-inflammatory th1 cells (2001) (0)
T helper 9 cell development is dependent on the T cell maturation stage (152.13) (2011) (0)
[Recommendations of the German Society of Rheumatology on therapy of pulmonary hypertension in patients with autoimmune diseases]. (2005) (0)
OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies (2018) (0)
FRI0065 Anti-tnf alpha monoclonal antibodies alter the activation and differentiation pattern of monocytes in patients with rheumatoid arthritis (2001) (0)
An approach to validating criteria for proteinuric flare in systemic lupus erythematosus glomerulonephritis: Commentary (2011) (0)
[Diagnostic and prognostic significance of antibodies against citrullinated peptides]. (2006) (0)
AB0257 Genetic effects of HLA-DRB1, IL4R, and FCΓRIIB on long-term treatment responses in patients with early rheumatoid arthritis: 78-week results of optima (2013) (0)
Th1-Biased Immune Responses In Vivo: A Generation and Regulation of Human (2013) (0)
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study - Commentary (2011) (0)
Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments: Commentary (2010) (0)
[Obituary from the German Society for Rheumatology for Prof. Joachim R. Kalden]. (2021) (0)
THU0008 Hypermethylation of Treg-Specific Demethylated Regions in the Ikaros Transcription Factor Family Members, Helios and EOS, in Rheumatoid Arthritis Tregs (2015) (0)
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials - Commentary (2011) (0)
[Characteristic symptoms of inflammatory rheumatic diseases]. (2020) (0)
Commentary Where is biological therapy going (2000) (0)
Regulation of myeloid cell function and MHC class II expression by tumor necrosis factor (2005) (0)
Reliability and construct validity of ultrasonography of soft tissue and destructive changes in erosive osteoarthritis of the interphalangeal finger joints: A comparison with MRI - Commentary (2011) (0)
Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections - Commentary (2011) (0)
Relapses and recurrences in giant cell arteritis: A population-based study of patients with biopsy-proven disease from northwestern Spain: Commentary (2011) (0)
34346 Pooled safety analysis of respiratory tract infections, including COVID-19, in psoriasis patients treated with secukinumab (2022) (0)
POS1246 COVID-19 IN RITUXIMAB TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES (2022) (0)
[Rheumatological side effects of checkpoint inhibitors and their treatment]. (2023) (0)
SAT0160 Prediction of Remission and Low Disease Activity in Dmard-Refractory Patients with RA Treated with Golimumab (2015) (0)
SAT0059 High radiographic progression is rare and gets less frequent in ra patients of the swiss scqm cohort from 1998 to 2015 (2017) (0)
Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades: Commentary (2011) (0)
AB0738 Concordance of greyscale and powerdoppler modes in ultrasound assessment of ra: significantly better performance of the dorsal versus palmar approach to mcp and pip joints (2013) (0)
Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the hand: An ultrasonographic study. Commentary (2010) (0)
Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis: Commentary (2011) (0)
POS0692 IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN’S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL (2021) (0)
OP0143 Genetic determinants of the th1 bias in rheumatoid arthritis (2001) (0)
Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial - Commentary (2011) (0)
What factors influence long-term survivorship after hip arthroscopy? Commentary (2011) (0)
Response to Methotrexate and Glucocorticoid Injection in New Onset Arthritis after Checkpoint Inhibitor Therapy (2017) (0)
[Rheumatology today - a dynamic discipline for the patients' good]. (2011) (0)
[Prevalence and treatment of rheumatological adverse events due to immune checkpoint inhibitor therapy]. (2020) (0)
AB0205 Il-22 Serum Levels as A Biomarker for Erosive Disease in Rheumatoid Arthritis (2016) (0)
OP0118 Altered T Cell Plasticity Favors TH17 Cells in Rheumatoid Arthritis (2015) (0)
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Commentary (2011) (0)
P088 TGFB bound to GARP promotes acetylation-mediated FOXP3 protein stabilisation (2018) (0)
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases (2023) (0)
Changes in liver biochemistry during methotrexate use for inflflammatory bowel disease: Commentary (2010) (0)
SAT0067 Radiographic Damage and Disability in Patients with Ra in Relation To Disease Duration in The Era of Biologics. Long-Term Results from The SCQM Cohort (2016) (0)
Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies: Commentary (2010) (0)
O26 Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial (2019) (0)
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID) (2015) (0)
AB0990 Automated Ultrasound for the Detection of Synovitis in the Feet of Patients with Rheumatoid Arthritis (RA) (2014) (0)
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept: Commentary (2011) (0)
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE: Commentary (2010) (0)
Skin cancers associated with autoimmune conditions among elderly adults: Commentary (2010) (0)
Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases: Commentary (2011) (0)
36 Operative Therapie (2012) (0)
THU0023 Antigen independent generation of immuno-modulatory th2 cells is regulated by map kinase activation and il-4 (2001) (0)
[Treatment of autoimmune diseases and graft rejection with anti-CD4 antibodies]. (1992) (0)
A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY (2020) (0)
THU0119 Rheumatoid arthritis myeloid cells express an intrinsic abnormal capacity for activation (2001) (0)
Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: A post hoc analysis of randomized clinical trial data - Commentary (2011) (0)
PFAPA syndrome is not a sporadic disease: Commentary (2011) (0)
Viewpoint Lymphopenia and autoimmune diseases (2004) (0)
All cause and disease specific mortality in patients with knee or hip osteoarthritis: Population based cohort study: Commentary (2011) (0)
Increased Th17 cell activity in patients with early rheumatoid and psoriatic arthritis (137.30) (2009) (0)
FRI0496 Does long distance running cause joint effusion of the knees and ankles? the munich marathon experience (2013) (0)
THU0117 The bias for th1 differentiation of rheumatoid arthritis t cells is characteristic of memory but not of naive t cells (2001) (0)
FRI0051 Application of a multiplex gene polymorphism assay for variants associated with rheumatoid arthritis susceptibility - results of 168 snps tested in the optima study (2013) (0)
The neuropeptide npT1 is specifically expressed in human CD25+ regulatory T cells (89.5) (2009) (0)
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans: Commentary (2011) (0)
SAT0183 Patient Reported Outcomes (PRO) of the Mirai: Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed by Rituximab in DMARD-IR Patients with Rheumatoid Arthritis (MIRAI) (2015) (0)
Differentiation of human peripheral blood memory T cells into TH2 effecters is dependent on IL-4 and stimulation by CD28 and is inversely correlated to the strength of T cell receptor ligation (1997) (0)
Defining Epigenetic Regulation of the Interleukin-9 Gene by Chromatin Immunoprecipitation. (2017) (0)
Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab: Commentary (2011) (0)
FRI0207 Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate, methotrexate alone or placebo: the dinora trial (2017) (0)
AB1037 CANAKINUMAB FOR TREATMENT OF ADULT ONSET STILL‘S DISEASE-RESULTS OF THE 24 WEEKS TREATMENT AND BEYOND: A MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER) (2020) (0)
Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis: Commentary (2011) (0)
Regulation of T-cell differentiation by IL-4R α-chain single nucleotide polymorphisms (2005) (0)
Acquisition of the rheumatoid arthritis HLA shared epitope through microchimerism: Commentary (2011) (0)
Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis: Commentary (2011) (0)
P111 Exploratory Analysis of Filgotinib Safety Data in Patients With Moderately to Severely Active Rheumatoid arthritis and an Increased Risk of Cardiovascular Events: Data From Phase 2 and 3 Clinical Trials (2023) (0)
The relationship between oral contraceptive use and functional outcome in women with recent-onset inflammatory polyarthritis: Results from the Norfolk Arthritis Register - Commentary (2011) (0)
[Presentation of the Erlangen Competence Center]. (2001) (0)
OP0231 Heart involvement in scleroderma patients and mice models (2013) (0)
FRI0070 Evaluation of a patient reported outcome (PRO) based tool for the assessment of single joint intraarticular glucocorticosteroid injection (2013) (0)
OP0223 Increased TH17 Cell Frequency and Poor Clinical Outcome in Rheumatoid Arthritis Are Associated with A Genetic Variant in the IL-4R Gene, Rs1805010 (2014) (0)
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis: Commentary (2011) (0)
Risk of cancer in inflflammatory bowel disease treated with azathioprine: A UK population-based case-control study - Commentary (2010) (0)
GATA-3 in human T helper cell type 2 development (2004) (0)
The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases: Commentary (2011) (0)
Inter-observer reliability of high-resolution ultrasonography in the assessment of bone erosions in patients with rheumatoid arthritis: Experience of an intensive dedicated training programme - Commentary (2011) (0)
Elevated expression of the Th17 cytokine interleukin 22 in rheumatoid arthritis (2010) (0)
Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: Results from a case-control study. Commentary (2010) (0)

This paper list is powered by the following services:

Hendrik Schulze‐koops's Academic­Influence.com Rankings

Hendrik Schulze‐koops's Degrees

Why Is Hendrik Schulze‐koops Influential?

Hendrik Schulze‐koops's Published Works

Published Works

Hendrik Schulze‐koops's AcademicInfluence.com Rankings